Eptacog alfa

Drug Profile

Eptacog alfa

Alternative Names: Activated recombinant human factor VII; Factor VIIa; NiaStase; NN 007; NovoSeven; NovoSeven RT; NovoSeven RT with MixProT; NovoSeven with pre-filled syringe; Novostase; Recombinant factor VIIa; rFVIIa

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage; Haemophilia; Thrombasthenia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Factor-VII-Deficiency; Haemophilia; Thrombasthenia
  • Discontinued Haemorrhage

Most Recent Events

  • 07 Jul 2014 Registered and launched for Glanzmann's thrombasthenia in USA (IV)
  • 31 Oct 2012 The EMA and the FDA approves eptacog alfa (NovoSeven®) for use in a pre-filled syringe for the treatment of Haemophilia in the USA and the EU
  • 04 Jan 2012 Launched for Haemophilia in India (IV) before 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top